INTRODUCTION
Since the introduction of chlordiazepoxide in medical and psychiatric practice in 1960, the indications for benzodiazepines expended. Except in psychiatry, benzodiazepines are used in neurology, internal medicine and cardiology, anesthesiology, physical therapy and doi:10.5937/hpimj1502261R other domains. Th e prevalence of long-term use, mostly large doses of benzodiazepines in the general population is 2-7% and among people who use benzodiazepines 25-76% [1] . With the increase in applications grew problems related to benzodiazepines: intoxication (accidental and intentional) and addiction (iatrogenic and non-iatrogenic). All benzodiazepines have the potential to create addiction on the term that those with short duration effect cause addiction more frequently and faster (primarily midazolam, lorazepam). In 15-44% of people on long-term (4-6 weeks) taking benzodiazepines, will be present a moderate to severe withdrawal syndrome aft er abrupt discontinuation of benzodiazepines [2] . It is a serious medical condition with polymorphic symptoms that require drug treatment.
Initial abstinence syndrome is 2-5 days aft er discontinuation and the symptoms can be present for several weeks. Most of the symptoms are not specifi c: there are insomnia, restlessness, irritability, fear, apathy and lethargy, nausea, tremors, muscle tension, sweating, rapid heartbeat. Increased sensitivity to noise, light and other stimuli are specifi c. Th ere may be more diffi cult and more serious disorders: epileptic seizures grand mal type, hallucinations, delirium, psychomotor agitation, delusions and suicidal thoughts [3.4] .
CASE REPORT
Th e patient, aged 48 years, was admitted for psychiatric evaluation and treatment of benzodiazepine addiction in specialist psychiatric clinic.
In history, the main problems were hand tremor, anxiety, agitation, anxiety, moodiness, pessimistic thoughts as well as the general decline in effi ciency and functionality by severe absenteeism in professional activities.
Present illness lasts from early adolescence; it was diagnosed as anxiety disorder and was not treated at that time. Aft er moving out of Serbia abroad in 1992, together with her family, fear, insecurity and her physical symptoms worsened and then she started on her own initiative to take anxiolytics, occasionally at fi rst, later every day, increasing the dose and oft en combining with alcohol, primarily in order to function at work (hand tremor disabled her professional activities). She was treated for the fi rst time in 2007 psychiatrically in her country due to immoderate drinking of alcoholic beverages and taking large doses of benzodiazepines (clonazepam of up to 14 mg. per day). Since then, she does not drink alcohol but a few months aft er she started taking clonazepam in daily doses of 6 to 12 mg. and to this treatment she has taken it practically continuously (abstinence extremely rare and short-lived, 2-3 days). For the second time, she was psychiatrically treated in Serbia, 2010, due to persistence of anxiety disorders while taking clonazepam she presented as sporadic to her therapist. Upon her return to native country, she continued taking clonazepam in larger doses. Th erapeutic doses prescribed by her physician, were modifi ed with clonazepam, which she purchased on the 'black market' . She recently managed to reduce the daily dose of clonazepam at 5-7 mg, with regular therapy venlafaxine 150 mg daily (prescribed by the doctor). In the personal history of the regular development, she is successful in education, from childhood prone to fears, uncertain, anxious in social situations. She graduated from medical school and she is working in the country of residence as a nurse. Her marriage is satisfactory and she has an adult daughter. Th e family history has no signifi cant psychiatric diseases.
On admission, mental status is dominated by symptoms and signs of anxiety, dysphoria, depressed ideation, with a mild psychomotor retardation and initial withdrawal symptoms. Insight was adequate; she was motivated for detoxifi cation of anxiolytics.
Th e patient was diagnosed as anxiodepressive disorder F 41.2 and addiction on benzodiazepines F13.2.
Given the dual diagnosis and duration of both disorders for signifi cantly long period of time in the past, failure of previous treatment because of apparent withdrawal symptoms and basic Anxio depressive disorder, the intention of the patient was accepted to carry out detoxifi cation of benzodiazepines. Protocol fl umazenil [5, 6] was suggested to her, with the adjuvant medication in the hospital conditions.
Protocol started aft er routine internistic assesment. and with the consent of the patient prior informed (information on all aspects of this method). Venous line was established and the initial dose of 1 mg of fl umazenil was applied in 500 ml of saline through several hours of infusion. According to the protocol, over the next four days fl umazenil was administered in a daily dose of 2 mg, with permanent monitoring of psychological and physical condition. In order to prevent the risk of seizures and an additional antianxiety and antidepressant activity, the patient was administered upon receiving lamotrigine fast-track scheme to 125 mg per day for three days, and it was continued with the same level onwards. During the entire period, vital signs were stable and psychological status was not registered as psychopathological problems.
Th e patient did not verbalize subjective symptoms therefore the initial high motivation was maintained.
On the fi ft h day, patient was discharged in stable psycho-physical condition. Aft er seven days, once was administered 2 mg of fl umazenil in an hours-long infusion with the idea to further stabilize the benzodiazepine receptors.
In terms of hospitalization, psychotherapy process was modifi ed and reduced to a support level, ventilation, maintenance of motivation and preparation for appropriate prolonged psychotherapeutic process. Implemented protocol was extremely successful and safe to which certainly contributed highly motivated patients and psychiatric preparation before hospitalization and support during hospitalization, both from professional and social network.
Th e procedure was carried out in 2014 and immediately upon release is included in the REBT (rational-emotional-behavioral therapy), which is still on going. Annual monitoring suggests maintaining abstinence and that in family, social and professional sense it is not only reintegrated but also completely functional.
DISCUSSION
Th e treatment of benzodiazepine withdrawal syndrome is a complex and serious medical problem. Faced with this, clinicians have developed several protocols for treatment. Th e initial clinical approach to a sudden discontinuation is replaced by a reductive scheme of diff erent duration, with or without the support of other psychopharmaceuticals. Benzodiazepine dose is reduced or benzodiazepine is introduced with longer eff ect of equivalent dose or other drugs are introduced (primarily psychostabilizers -lamotrigine, carbamazepine, valproate) administered upon discontinuation of benzodiazepine. Long-term substitution treatment in people at high doses of benzodiazepines and the structural changes of personality [7] is less commonly implemented. Th e main drawback of this approach is the very length of detoxifi cation, which can range from 2-3 weeks to several months, which greatly aff ects the efficiency and comfort of the procedure. Due to the possible presence of abstinence problems and desire for eff ects, people oft en forgo treatment and return to taking benzodiazepines.
From pioneering protocols introduced by Gilberto Gerra (working at Centro Studi Farmacotoxico Substance Abuse Service, Parma, Itally) [8, 9] Further clinical practice and research confi rms that fl umazenil mainly acts as a "silent" receptor antagonist on the benzodiazepine receptor of the GABA-A complex, and is active only in the presence of benzodiazepines, replacing them, which explains its eff ect on reducing withdrawal symptoms and anxiety reduction. However, in certain circumstances, the modifi cation in the receptor complex GABA-A, which is the case with the long-term anxiety disorders (in panic disorder primarily) or in cooperation with chronic use of benzodiazepines, it can act as a benzodiazepine inverse agonist, i.e. increased anxiety [12] . Clinical effect of fl umazenil therefore varies depending on the circumstances and basic disorder in a patient. Also, there are indications that fl umazenil has the ability to reduce prolonged symptoms of benzodiazepine withdrawal syndrome sometimes a few months (or longer) aft er discontinuation of polymorphic persistence www.hophonline.org of symptoms [13, 14, 15] . Th e assumption is that fl umazenil can 'reset 'benzodiazepine receptor functions. Particularly, the chronic (high) doses of benzodiazepines lead to allosteric alterations of benzodiazepines receptors and reduce affi nity both for the benzodiazepine receptors and for GABA receptors in GABA-A macromolecular receptors complex. Flumazenil works by replacing (suppressing) the benzodiazepine from receptors and possibly inducing 'up regulation' of benzodiazepine receptors leading to their normalization [6.9] . Despite the good results so far, many aspects of this procedure must be tested and [15] , it is necessary to answer the numerous questions: -In respect of which doses and length of taking benzodiazepines should be recommend and implemented fl umazenil protocol? -Should fl umazenil protocol be used only if the reduction of benzodiazepines does not work? -Can the protocol be adopted also for those with a history of seizures? -How to optimize the dose of fl umazenil as well as the length and route of administration? For now, it is thought that better long-term effects are achieved by administration (during the day), while the overall length of treatment remains open question.
-What adjuvant medications can optimize treatment? -Is there any justifi cation for thinking about longer-lasting treatment of fl umazenil as other partial agonists -buprenorphine successfully implemented in the treatment of opiate addiction and varenicline addiction on nicotine?
In conclusion, addiction on benzodiazepines today represents a signifi cant medical -psychiatric problem and most prominent form of iatrogenic addiction, while the treatment of benzodiazepine apstinential syndrome is complicated and has uncertain outcomes. As fl umazenil protocol gave promising results, further studies and approvement of clinical studies with a larger number of subjects are needed which will confi rm the applicability, effi cacy and safety of this method.
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KRATAK SADRŽAJ
Uvod: Danas u svetu kao i u Srbiji raste broj osoba koje su zavisne od benzodiazepina. Poseban problem predstavlja proces detoksikacije odnosno tretman benzodiazepinskog apstinencijalnog sindroma zbog povratka simptoma anksioznog poremećaja, dostupnost benzodiazepina, pada motivacije. Standardne procedure su se često pokazale neuspešnim pa se poslednjih desetak godina u svetu traga za novim protokolima medju kojima je i fl umazenil, antagonist benzodiazepinskih receptora. Prikaz slučaja: Pacijentkinja stara 48 godina je primljena u specijalističkoj psihijatrijskoj ordinaciji, radi tretmana zavisnosti od benzodiazepina. Dijagnostikovan je anksiozni poremećaj od adolescencije višegodišnja zavisnosti od benzodiazepina i početni apstinencijalni sindrom. Dosadašnji tretmani neuspešni, aktuelno motivisana za detoksikaciju. Prisutnost dualne dijagnoze, perzistencija oba poremećaja u višegodišnjem periodu, teraporezistencija i aktuelna motivisanost su opredelili odluku o brzoj detoksikaciji od benzodiazepina, primenom protokola fl umazenilom, u hospitalnim uslovima, uz adjuvantu terapiju lamotriginom. Po otpustu u stabilnom stanju, bez znakova apstinencijalnog sindroma i rebound anksioznih simptoma. Nastavljena je medikacija lamotriginom, uključena CBT, tokom jednogodišnjeg praćenja održava apstinenciju, uz zadovoljavajuću socijalnu funkcionalnost. Diskusuja: Efi kasnost i bezbednost fl umazenila u tretmanu benzodiazepinskog apstinencijalnog sindroma je ispitivana u brojnim kliničkim studijama, dok je mehanizam dejstva složen, od benzodiazepinskog antagonista, do inverznog agonista u određenim okolnostima, kao i "up-regulation" receptora, što zajedno dovodi do smanjenja simptoma apstinencijalnog sindroma i anksioznosti i u dužem periodu po tretmanu, delujući time povoljno na adherencu i remisiju. Zaključak: Flumazenil protokol predstavlja efi kasnu metodu u tretmanu benzodiazepinskog apstinencijalnog sindroma. S obzirom na postojanje odredjenih nedoumica i relativno mala iskustva u ovoj proceduri, neophodno je dalje defi nisanje svih aspekata procedure.
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